Trial results for a study investigating an MRI protocol for breast cancer screening were posted on ClinicalTrials.gov on 2026-03-20. The study was terminated, having enrolled 166 participants.
Background
Breast cancer remains a significant health concern, and early detection is crucial for improving outcomes. Traditional screening methods like mammography can have limitations, particularly in women with mammographically dense breasts, where cancer can be harder to detect. This can lead to missed cancers or interval cancers, which are detected between scheduled screenings. Magnetic Resonance Imaging (MRI) has shown potential to offer increased sensitivity in detecting breast cancer, especially in dense breast tissue, and could lead to earlier detection and potentially reduced mortality.
Trial design
This terminated study enrolled 166 participants to test an innovative MRI breast cancer screening method. The trial focused on women with mammographically dense breasts and those with moderately increased cancer risk, aiming to improve sensitivity to cancer detection and reduce interval cancers compared to mammography.
Key results
The trial reported one key measurement:
- For the outcome 'True Positive' in the 'MRI Unknown Cancer Status Group':
- A mean of 0.09 (Standard Deviation 0.03) true positive scans was observed.
What this means
The posted results provide a specific measurement for true positive scans from the terminated study. With a mean true positive rate of 0.09, this initial data point contributes to the understanding of the innovative MRI protocol's performance. However, due to the trial's termination and the limited scope of the reported results, comprehensive conclusions regarding its broader clinical implications for breast cancer screening cannot be drawn from this data alone.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04877912, titled 'Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening', were posted on 2026-03-20 on clinicaltrials.gov.
